Cargando…

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia

OBJECTIVE: To assess the effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine (RAIM) in patients with acute agitation associated with schizophrenia in a real-world clinical setting. METHODS: The postmarketing surveillance study with a 3-day ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katagiri, Hideaki, Taketsuna, Masanori, Kondo, Shinpei, Kajimoto, Kenta, Aoi, Etsuko, Tanji, Yuka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922248/ https://www.ncbi.nlm.nih.gov/pubmed/29719399 http://dx.doi.org/10.2147/NDT.S158339

Ejemplares similares

Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri, Hideaki, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2014)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2013)

Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness
por: Williams, Andrew M.
Publicado: (2018)

Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
por: Patel, Seema M., et al.
Publicado: (2021)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial
por: Chan, Esther W., et al.
Publicado: (2021)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Intramuscular Olanzapine – a UK case series of early cases
por: Bushe, Chris J, et al.
Publicado: (2007)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

IVIVC from Long Acting Olanzapine Microspheres
por: D'Souza, Susan, et al.
Publicado: (2014)

Pharmacovigilance on olanzapine
por: Lingeswaran, Anand, et al.
Publicado: (2010)

Teratogenicity with Olanzapine
por: Prakash, Sathya, et al.
Publicado: (2014)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
por: Lu, Mong-Liang, et al.
Publicado: (2013)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Olanzapine Induced Hyponatraemia
por: Dudeja, Sonia J, et al.
Publicado: (2010)

Olanzapine-Induced Neutropenia
por: Malhotra, Kirti, et al.
Publicado: (2015)

Olanzapine-induced Psoriasis
por: Chepure, Ashish Hanmantrao, et al.
Publicado: (2017)

Seizure associated with olanzapine
por: Uvais, N. A., et al.
Publicado: (2018)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia
por: Tajiri, Misuzu, et al.
Publicado: (2018)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
por: Hindmarsh, Jonathan, et al.
Publicado: (2020)

Prevalence of diabetes in patients of Schizophrenia on long-term use of olanzapine
Publicado: (2022)

Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H
por: Zhang, Yi, et al.
Publicado: (2023)

Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial
por: Phyland, Ruby K, et al.
Publicado: (2020)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qbtdb3a4vl5oou7v9jnmb57q1l